Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia

American Journal of Hematology

Volumn 91, Issue 6, 2016, Pages E312-E313

  Gustine, Joshua N ^a   Meid, Kirsten ^a   Dubeau, Toni E ^a   Treon, Steven P ^a,b   Castillo, Jorge J ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLUCOCORTICOID; IBRUTINIB; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PROTEASOME INHIBITOR; WARFARIN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABLATION THERAPY; ADULT; AGED; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; CARDIOVERSION; DRUG DOSE REDUCTION; DUAL CHAMBER PACEMAKER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; RISK FACTORS; TIME FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84966727909     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24366     Document Type: Letter

References (6)

1. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015;372:1430-1440.
2. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet 2015;386:154-162.
3. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-223.
4. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425-2437.
5. Farooqui M, Valdez J, Soto S, et al. Atrial fibrillation in CLL/SLL patients on ibrutinib [abstract]. Blood 2015;126:Abstract 2933.
6. McMullen JR, Boey EJH, Ooi JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124:3829-3830.